added in 200 μL of DMEM. Each insert was placed in a well that contained 650 μL of DMEM. Migration assays were begun 90 minutes after seeding with the addition of either 40 ng/mL of platelet-derived growth factor-BB (R&D Systems, Minneapolis, MN) or 10% FBS, plus either a test reagent (added to both compartments of the transwell chamber) or a matched control containing an equivalent concentration of vehicle (dimethyl sulfoxide). Cells were incubated for 17 hours (with FBS) or 5 hours (with platelet-derived growth factor). In control experiments, total cell number and viability were checked with a Countess Cell Counter (Life Technologies). Migrated cells on the bottom surface of the insert were identified using a Diff-Quik Stain set (Siemens Healthcare Diagnostics Inc, Newark DE); 1 minute in fixative, 2 minutes in solution I, and 4 minutes in solution II followed by rinsing in distilled water. Six 132-mm 2 sections of the inserts were imaged by bright field microscopy (×20 objective), and then the number of migrated cells was counted; values from the 6 different areas were averaged. All of the current/voltage data were statistically analyzed by ANOVA with a Bonferroni post hoc test. Other data were analyzed with a Student t test. In the figure legends, n indicates the number of experiments. Values of P<0.05 were considered significant.
Results

Cell Migration of Wild-Type and ClC-3 Null Aortic VSMCs
We have investigated whether ClC-3 influences the migration of VSMCs in transwell assays. Cells were obtained from both wild-type and ClC-3 null mice; the success of the gene disruption is illustrated by Western analysis ( Figure 1A ). Cell migration in response to platelet-derived growth factor, a promigratory stimulus, 14 was substantially reduced in ClC-3 null cells compared with wild-type cells ( Figure 1B through 1D ). That same phenotype was also observed in an experimental paradigm (serum-stimulated migration) 15, 16 that more closely mimics the complex growth factor environment in vivo ( Figure  1E through 1G). The reduced migration of ClC-3 null cells was not an indirect consequence of there being fewer cells (see legend to Figure 1 ). Thus, the ClC-3 null cells did not proliferate more slowly. The latter observation is consistent with a previous 2 conclusion that disruption of the ClC-3 gene did not affect VSMC proliferation per se, although it specifically halved the proliferative response to the proinflammatory cytokine, tumor necrosis factor-α. 19 or absent ( Figure S1 , available in the online-only Data Supplement). We next measured I Cl.Ca in wild-type and ClC-3 null cells using medium containing BAPTA (1,2-bis(oaminophenoxy)ethane-N,N,N',N'-tetraacetic acid) to buffer [Ca 2+ ] IN (inset to Figure 2A ] IN , whole-cell current was increased in both cell types (Figure 2A and 2B). I Cl.Ca was outwardly rectifying ( Figure 2A and 2B); kinetic analysis ( Figure S2 ) revealed time-dependent activation of Cl -currents at depolarizing potentials. These are the prototypical characteristics of I Cl.Ca . [20] [21] [22] [23] [24] These kinetic properties were not significantly affected by disruption of the ClC-3 gene ( Figure S2 ). I Cl.Ca was ≈50% smaller in ClC-3 null VSMCs than in wildtype cells (Figure 2) . It has not been demonstrated previously that I Cl.Ca is decreased after knockout of the ClC-3 gene in any cell type. Thus, we highlighted this novel result by depicting steady-state currents at −100 mV and +40 mV ( Figure 2C ). We chose these voltages because they are equidistant from the E Cl at −31 mV; although opposite in polarity, the 2 resultant currents are elicited by electrical driving forces that are equal in magnitude. We conclude that I Cl.Ca in the wild-type cells is composed of approximately equal contributions from both ClC-3-dependent and ClC-3-independent components ( Figure S3) . A generic Cl -channel blocker, niflumic acid, 25 inhibited I Cl.Ca in both cell types (Figure 2A and 2B) . Niflumic acid also inhibited serum-stimulated migration in the wild-type cells ( Figure 2D) ; cell numbers and viability were not affected by niflumic acid (Figure 2 legend) . Niflumic acid did not alter migration in ClC-3 null cells ( Figure 2D ). Our data suggest that the ClC-3-dependent component of I Cl.Ca contributes to VSMC migration ( Figure S3 ). Figures 3A and S4) . Significantly, KN-93 did not affect I Cl.Ca in the ClC-3 null cells ( Figure 3B ). Control experiments indicated that there were similar degrees of CaMKII activity in the 2 cell types ( Figure S5 ). Thus, in aortic VSMCs, endogenous CaMKII mediates Ca 2+ -dependent activation of I Cl.Ca through a ClC-3-dependent process ( Figure S3 ).
Swelling-Activated and
Regulation of I
In certain cell types, the degree to which CaMKII activates I Cl.Ca is supervised by Ins(3,4,5,6)P 4 10,11,20 ; cellular levels of Ins (3, 4, 5, 6) Figure S3 ). Instead, Ins(3,4,5,6)P 4 specifically prevents CaMKII from activating I Cl.Ca . 11, 20 This is a receptor-coupled mechanism by which Ins(3,4,5,6)P 4 regulates salt and fluid secretion, insulin release, and neuronal excitability. 11, 20 A physiologically relevant 11 concentration of 10 μM Ins(3,4,5,6)P 4 reduced the size of I Cl.Ca by 40% to 50% ( Figure 3A ). The inhibitory effects of KN-93 and Ins(3,4,5,6)P 4 on I Cl.Ca were not additive ( Figures 3A and S6 ), consistent with the end point for both agents being inhibition of ClC-3 activity, Ins(3,4,5,6)P 4 did not affect swelling-activated Cl -currents in VSMCs ( Figure S1 ), which are not dependent on ClC-3 ( Figure S1 ). Moreover, Ins(3,4,5,6)P 4 did not alter I Cl.Ca in the ClC-3 null cells ( Figure 3B ). These results provide important information concerning the specificity of Ins(3,4,5,6)P 4 action; it has not been shown previously that ClC-3 is absolutely required for Ins(3,4,5,6)P 4 to regulate I Cl.Ca . Overall, our data demonstrate that ClC-3 provides VSMCs with a specific signaling mechanism by which Ins(3,4,5,6)P 4 and CaMKII can regulate one component of I Cl.Ca ( Figure S3 ).
Regulation of ClC-3 and the Migration of Aortic VSMCs
CaMKII is known to regulate VSMC motility. 3 We next investigated whether the regulation of migration by CaMKII requires ClC-3. We again used serum as a promigratory stimulus; serum drives VSMC migration in vitro by elevating intracellular [Ca 2+ ] and activating CaMKII.
3,14-16,32 When we added increasing concentrations of KN-93 (10-100 μM) to inhibit CaMKII, we found dose-dependent inhibition of migration of wild-type cells (maximal effect, 45%; Figure 4A ); KN-93 did not alter the number or the viability of wild-type cells at the highest dose used (Figure 4 legend) . Significantly, 10 to 50 μM KN-93 did not affect migration of ClC-3 null cells ( Figure 4B ). These data substantiate our conclusion that CaMKII regulates cell migration through ClC-3 ( Figure S3 ).
At its maximal dose of 100 μM, KN-93 slightly inhibited the migration of ClC-3 null cells ( Figure 4B ), an effect that was possibly related to the 22% decrease in cell number at this concentration (Figure 4 legend) . We next added Ins(3,4,5,6)P 4 , which does not inhibit CaMKII per se, but instead selectively prevents the activation of ClC-3 by CaMKII. 10, 20 A total of 10 μM Ins(3,4,5,6)P 4 inhibited migration of wild-type cells by 48% ( Figure 4C ), without affecting cell number or viability (legend to Figure 4 ). Ins(3,4,5,6)P 4 did not inhibit migration in ClC-3 null cells ( Figure 4D ), further supporting our conclusion that ClC-3 regulates VSMC migration.
Discussion
Our study makes a number of new observations concerning the importance of ClC-3 and Ins(3,4,5,6)P 4 for plasmalemmal Cl -flux (I Cl.Ca ) and cell motility in VSMCs. Our results provide the first demonstration, in any cell type, that the size of I Cl.Ca is substantially decreased after disruption of the ClC-3 gene ( Figure 2 ). It is also a novel finding that endogenous CaMKII acts through ClC-3 to stimulate I Cl.Ca in a smooth muscle cell line ( Figure S3 ). This new information concerning ClC-3 is important because spatio-temporal control of ion channels and transporters is key to the process of cell migration.
4,5 Indeed, we report in this study that ClC-3 contributes to VSMC migration in a CaMKII-dependent manner (Figures 3 and 4) . Our study also adds to the known repertoire of biological functions of Ins(3,4,5,6)P 4 10 by showing that it regulates VSMC migration. Previous work 21 with parotid acinar cells indicated that I Cl.Ca was not affected by elimination of ClC-3. That result has been frequently interpreted as an indication that ClC-3 does not contribute to I Cl.Ca in any cell. [33] [34] [35] [36] [37] That assumption is now proved to be incorrect by our new data (Figure 2) . Clearly, the regulation of I Cl.Ca in aortic smooth muscle cells differs from that in parotid acinar cells, and we believe that CaMKII is the distinguishing factor: in our aortic smooth muscle cells, ClC-3-dependent activation of I Cl.Ca requires CaMKII (Figure 3) . In parotid acinar cells, CaMKII does not activate I Cl.Ca . 38 These differences between parotid cells and VSMCs in the role of CaMKII can explain why I Cl.Ca is differentially impacted by the elimination of ClC-3. Moreover, the activation of I Cl.Ca by CaMKII in aortic smooth muscle cells also uncovers a new aspect of signaling specialization in vascular biology. Previous work 23, 27, 29 has shown that CaMKII inhibits I Cl.Ca in smooth muscle cells from the pulmonary artery.
There is a long-standing debate as to whether ClC-3 is either directly responsible for plasmalemmal I Cl.Ca 26 or instead indirectly regulates Cl -flux. 34 Elsewhere 39 it has been explained why it is difficult to unequivocally prove whether a protein is either directly responsible for an ion current or instead contributes to a process that regulates another channel. It is beyond the scope of our study to resolve this complex question. Nevertheless, our results indicate that the halving of I Cl.Ca on disruption of the ClC-3 gene (Figure 2 ) reflects the loss of a specific signaling pathway, namely, CaMKII-dependent I Cl.Ca . Consistent with that conclusion, ClC-3-dependent I Cl.Ca was blocked by the addition of a CaMKII inhibitor, KN-93 (Figure 3 ) or by Ins(3,4,5,6)P 4 , an intracellular signal that specifically attenuates ClC-3 activation by CaMKII (Figures 3 and S3 ). Our study shows that total I Cl.Ca in VSMCs includes a component that is CaMKII and ClC-3 dependent and another component that is independent of both CaMKII and ClC-3 ( Figure S3 ). The latter may reflect that portion of I Cl.Ca that is directly activated by Ca 2+ . 35, 40, 41 Unlike Ca 2+ , CaMKII is particularly suited for regulating longer-term responses, because the kinase can remain active (autonomous) even in a poststimulation context, at a time when [Ca 2+ ] IN has returned to resting levels. 42 That CaMKII memory could explain why the CaMKII-dependent portion of I Cl.Ca , which is mediated by ClC-3, is important to a sustained biological activity such as cell migration. Nevertheless, there may be additional targets by which CaMKII regulates migration. 3 Finally, our data are very relevant to an earlier study showing that ClC-3 null mice are less susceptible to neointima formation after carotid ligation. 2 That phenotype was attributed to a reduced rate of tumor necrosis factor-α-dependent proliferation of VSMCs. 2 Our new data suggest that reduced VSMC motility may be an important contributing factor. Both migration and proliferation of VSMCs contributes to vascular remodeling, 1 so our study provides new insight into the mechanisms underlying this condition.
Perspectives
The regulation of ClC-3 influences migration (see above) of VSMCs, which is a causal factor for diseases of vascular remodeling, such as the formation of neointima 2 and atherosclerosis.
1 ClC-3 may also drive glioblastoma pathophysiology 8 and cardiac hypertrophy. 17 Thus, genetic or pharmacological intervention in cell signaling by ClC-3 may ultimately benefit multiple aspects of human health. To this end, Ins(3,4,5,6)P 4 specifically prevents the activation of ClC-3 by CaMKII (see above) without altering CaMKII activity per se. 20 Moreover, the inositol phosphate did not affect either I Clswell ( Figure S1 ) or the ClC-3 independent portion of I Cl.Ca (Figure 2 ). We suggest that Ins(3,4,5,6)P 4 is a potential lead compound for synthesizing a drug that might inhibit vascular remodeling by specifically targeting ClC-3. 
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Disclosures
None. • Determination that a chloride channel/transporter, ClC-3, regulates plasmalemmal chloride flux and migration of VSMCs.
• Regulation of VSMC migration is a new biological function for an inositol phosphate (IP4).
• Identification of a promigratory substrate for calmodulin-dependent protein kinase II in VSMCs.
What Is Relevant?
• Identification of cellular factors that regulate migration of VSMCs, a key step in the vascular remodeling associated with hypertension.
• Increased understanding of neointima formation.
• Identification of a lead compound for drugs targeting vascular remodeling. In some experiments, ICl swell was specifically induced. In these experiments, the bath solution contained 145 mM NMDG-Cl, 2 mM MgCl 2 , 10 mM Hepes and 10 mM glucose, pH 7.4 (adjusted by adding 1M NMDG). The pipette solution (as described above, but with no added Ca 2+ ) was adjusted to 335 mOsm using 1M mannitol).
CaMKII assays
Cells were grown in 175 cm Fig. 2A,B) , close to the E Cl of -31 mV. In additional experiments we set E Cl to zero by having 145 mM Cl -in both the batch and pipette solutions. In these experiments, the reversal potential was shifted to -4.6 ± 3.6 mV (n=8), a result that is again consistent with our whole-cell currents reflecting transmembrane Cl -flux. The similarity of the kinetic properties of I Cl.Ca in the wild-type and ClC-3 null cells deserves comment. First, however, it should be noted that it is difficult to unequivocally prove whether a protein is either directly responsible for an ion current, or instead contributes to a process that regulates another channel (see ref 1 ).
Thus, even those involved in the cloning of the TMEM16 family 1, 2 and who have proposed that these proteins conduct plasmalemmal Ca 
